期刊
CHEMMEDCHEM
卷 7, 期 6, 页码 1002-1008出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cmdc.201200006
关键词
antibacterial agents; drug resistance; beta-lactamases; inhibitors; protein crystallography
资金
- Robert A. Welch Foundation, Houston, USA [N-0871]
- US National Institutes of Health [R01 AI062968, R01 AI063517-01]
- US Department of Veterans Affairs
- Cleveland Geriatric Research Education and Clinical Center (GRECC)
The ability of bacteria to express inhibitor-resistant (IR) beta-lactamases is stimulating the development of novel inhibitors of these enzymes. The 2'beta-glutaroxypenicillinate sulfone, SA2-13, was previously designed to enhance the stabilization of the deacylation-refractory, trans-enamine inhibitory intermediate. To test whether this mode of inhibition can overcome different IR mutations, we determined the binding mode of SA2-13 through X-ray crystallography, obtaining co-crystals of the inhibitorprotein complex by soaking crystals of the IR sulfhydryl variable (SHV) beta-lactamase variants S130G and M69V with the inhibitor. The 1.45 angstrom crystal structure of the S130G SHV:SA2-13 complex reveals that SA2-13 is still able to form the stable trans-enamine intermediate similar to the wild-type complex structure, yet with its carboxyl linker shifted deeper into the active site in the space vacated by the S130G mutation. In contrast, data from crystals of the M69V SHV:SA2-13 complex at 1.3 angstrom did not reveal clear inhibitor density indicating that this IR variant disfavors the trans-enamine conformation, likely due to a subtle shift in A237.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据